Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ARE
ARE logo

ARE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Alexandria Real Estate Equities, Inc (ARE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
51.030
1 Day change
3.70%
52 Week Range
88.240
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Alexandria Real Estate Equities, Inc. is not a strong buy at the moment for a beginner investor with a long-term focus. The stock faces significant headwinds, including analyst downgrades, declining FFO projections, and cautious trading activity from Congress members. While insider buying and positive employee-focused initiatives are encouraging, the technical indicators and options data suggest a neutral to slightly bearish sentiment. For a beginner investor, it would be prudent to wait for clearer positive signals or improved financial performance before considering a purchase.

Technical Analysis

The MACD is negatively expanding (-0.265), indicating bearish momentum. RSI is neutral at 48.348, and moving averages are converging, showing no clear trend. Key support is at 49.505, and resistance is at 54.303. The stock is trading near its support level, but no strong bullish signals are present.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The high Open Interest Put-Call Ratio indicates a slightly bearish sentiment, while the lower Option Volume Put-Call Ratio suggests more call activity relative to puts, indicating mixed sentiment.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
6

Positive Catalysts

  • Insider buying has increased by 651.34% over the last month.

  • The company is ranked 16th in talent readiness on The Wall Street Journal's 'Best Companies for the Future' list.

  • Positive employee-focused initiatives, such as leadership development and comprehensive benefits.

Neutral/Negative Catalysts

  • Multiple analyst downgrades and reduced price targets.

  • Projected FFO declines and headwinds in life science occupancy.

  • Congress trading data shows more selling activity than buying, indicating caution.

  • Technical indicators suggest bearish momentum.

Financial Performance

Financial data for the latest quarter is unavailable, but analysts project a 22% FY26/27 average FFO per share decline due to asset sales and rising interest costs.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed to negative. Recent downgrades include Morgan Stanley lowering the rating to Underweight with a $53 price target, and Baird downgrading to Neutral with a $46 price target. Price targets have been consistently revised downward, reflecting concerns about regulatory uncertainty, lease expirations, and oversupply in the life science real estate market.

Wall Street analysts forecast ARE stock price to rise
15 Analyst Rating
Wall Street analysts forecast ARE stock price to rise
3 Buy
12 Hold
0 Sell
Hold
Current: 49.210
sliders
Low
41
Averages
56.85
High
67
Current: 49.210
sliders
Low
41
Averages
56.85
High
67
BMO Capital
Market Perform
maintain
$52 -> $54
AI Analysis
2026-06-12
Reason
BMO Capital
Price Target
$52 -> $54
AI Analysis
2026-06-12
maintain
Market Perform
Reason
BMO Capital raised the firm's price target on Alexandria Real Estate to $54 from $52 and keeps a Market Perform rating on the shares as part of a broader research note on Gaming and Lodging names. World Cup anticipation has taken a back seat to strong RevPAR performance that suggests upside to Q2 results and outlooks even if World Cup upside fails to materialize, the analyst tells investors in a research note. At this point, World Cup expectations are fairly low and hotel prices have continued to moderate, moving lower at 70% of lodging REIT hotels since April, the firm added.
Morgan Stanley
Equal Weight -> Underweight
downgrade
$price
2026-06-11
Reason
Morgan Stanley
Price Target
$price
2026-06-11
downgrade
Equal Weight -> Underweight
Reason
Morgan Stanley downgraded Alexandria Real Estate to Underweight from Equal Weight.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ARE
Unlock Now

People Also Watch